

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : A61K 49/00		A1	(11) International Publication Number: WO 92/17212 (43) International Publication Date: 15 October 1992 (15.10.92)
(21) International Application Number:	PCT/EP92/00715		(74) Common Representatives: HOLMES, Michael, John et al.; Frank B. Dehn & Co., Imperial House, 15-19 Kingsway, London WC2B 6UZ (GB).
(22) International Filing Date:	28 March 1992 (28.03.92)		
(30) Priority data: 9106673.8	28 March 1991 (28.03.91)	GB	(81) Designated States: AT (European patent), AU, BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FI, FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, LU (European patent), MC (European patent), NL (European patent), NO, SE (European patent), US.
(71) Applicant (<i>for GB only</i>): HOLMES, Michael, John [GB/GB]; Frank B. Dehn & Co., Imperial House, 15-19 Kingsway, London WC2B 6UZ (GB).			
(71) Applicant (<i>for all designated States except US</i>): NYCOMED AS [NO/NO]; Nycoveien 2, P.O. Box 4220 Torshov, N-0401 Oslo 4 (NO).			Published <i>With international search report.</i>
(72) Inventors; and. (75) Inventors/Applicants (<i>for US only</i>) : KLAVENESS, Jo [NO/NO]; Skøyen terasse 15, N-0276 Oslo (NO). PRIEBE, Hanno [NO/NO]; Johan Castbergs vei 56, N-0673 Oslo (NO). RONGVED, Pål [NO/NO]; Hovdens vei 13, N-1454 Hellvik (NO). STUBBERUD, Lars [NO/SE]; Karlskovsvägen 7, S-151 37 Södertälje (SE).			

(54) Title: IMPROVEMENTS IN OR RELATING TO CONTRAST AGENTS**(57) Abstract**

Ultrasound contrast agents having microbubbles of gas or a gas precursor encapsulated by non-proteinaceous crosslinked or polymerised amphiphilic moieties, e.g. in the form of micelles, exhibit good stability *in vivo* upon administration and may if desired incorporate biodegradable linkages so as to possess particular desired levels of biodegradability.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MC	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	RU	Russian Federation
CG	Congo	KP	Democratic People's Republic of Korea	SD	Sudan
CH	Switzerland	KR	Republic of Korea	SE	Sweden
CI	Côte d'Ivoire	LI	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
DE	Germany	MC	Monaco	TG	Togo
DK	Denmark			US	United States of America

"Improvements in or relating to contrast agents"

- 5 This invention relates to novel contrast agents, more particularly to new gas-containing or gas-generating contrast agents of use in diagnostic ultrasonic imaging.
- 10 It is well known that ultrasonic imaging comprises a potentially valuable diagnostic tool, for example in studies of the vascular system, particularly in cardiography, and of tissue microvasculature. A variety of contrast agents has been proposed to enhance the
- 15 acoustic images so obtained, including suspensions of solid particles, emulsified liquid droplets, gas bubbles and encapsulated gases or liquids. It is generally accepted that low density contrast agents which are easily compressible are particularly efficient in terms
- 20 of the acoustic backscatter they generate, and considerable interest has therefore been shown in the preparation of gas-containing and gas-generating systems.
- 25 Initial studies involving free gas bubbles generated in vivo by intracardiac injection of physiologically acceptable substances have demonstrated the potential efficiency of such bubbles as contrast agents in echocardiography; such techniques are severely limited in practice, however, by the short lifetime of the free bubbles. Interest has accordingly been shown in methods of stabilising gas bubbles for echocardiography and other ultrasonic studies, for example using emulsifiers, oils, thickeners or sugars.
- 30
- 35 WO 80/02365 discloses the use of gelatin-encapsulated gas microbubbles for enhancing ultrasonic

- 2 -

images. Such microbubbles do not, however, exhibit adequate stability at the dimensions preferred for use in echocardiography (1-10 μm) in view of the extreme thinness of the encapsulating coating.

5

US-A-4774958 discloses the use of microbubble dispersions stabilised by encapsulation in denatured protein, e.g. human serum albumin. Such systems permit the production of microbubble systems having a size of 10 e.g. 2-5 μm but still do not permit efficient visualisation of the left heart and myocardium.

EP-A-0327490 discloses, inter alia, ultrasonic contrast agents comprising a microparticulate synthetic biodegradable polymer (e.g. a polyester of a hydroxy carbonic acid, a polyalkyl cyanoacrylate, a polyamino acid, a polyamide, a polyacrylated saccharide or a polyorthoester) containing a gas or volatile fluid (i.e. having a boiling point below 60°C) in free or bonded form. Emulsifiers may be employed as stabilisers in the preparation of such agents, but such emulsifiers do not chemically interact with the polymer.

We have now found that particularly effective ultrasonic contrast agents may be obtained by encapsulating gas bubbles or gas generating systems with polymers containing chemically linked surface active, i.e. amphiphilic, moieties. Thus the surface active properties of the amphiphilic groups stabilise the 25 microbubble system by reducing surface tension at the gas-liquid interfaces, e.g. by forming monolayers or one or more bilayers (alternatively known by the terms 30 micelles, vesicles, liposomes and niosomes) at said interfaces, while the linking of the groups through the 35 polymer system generates further stability. Flexibility of the encapsulating materials also enhances the image density afforded by such contrast agents. For

- 3 -

simplicity the terms "vesicle" is used herein to denote all such microbubble structures prior to or after cross-linking or polymerisation. It should be noted that under some conditions irregularly shaped structures may 5 be formed, e.g. microtubules which may join with or even entrap spherical structures.

Thus according to one aspect of the present invention there are provided contrast agents for use in 10 diagnostic ultrasound studies comprising microbubbles of gas or a gas precursor encapsulated by non-proteinaceous crosslinked or polymerised amphiphilic moieties.

The term "crosslinked" is used herein to denote 15 that the amphiphilic moieties are linked to each other to form a polymeric structure which may incorporate one or more polymer systems (including copolymers).

A major advantage of contrast agents according to 20 the invention is that they may be designed to a particular desired level of biodegradability in vivo by selecting appropriate biodegradable linkages at appropriate positions. It will be appreciated that in order to be effective the contrast agents must be stable 25 throughout the ultrasonic examination but are preferably metabolised or removed safely from the circulation system shortly thereafter. Contrast agents in accordance with the invention should thus preferably have a half-life in vivo of not more than 48 hours, for 30 example 1-12 hours.

Biodegradable linkages which may be present in 35 contrast agents according to the invention include amide, imide, imine, ester, anhydride, acetal, carbamate, carbonate, carbonate ester and disulphide groups. At least one such group should preferably be present in the amphiphilic moiety, in the hydrophilic

- 4 -

and/or lipophilic portion; it may be advantageous to position the group in the hydrophilic part to facilitate enzymic interaction in vivo. It is further preferred that biodegradable linkages be present in the polymer 5 backbone to ensure substantial breakdown of the polymer in the body.

Any biocompatible gas may be employed in the contrast agents of the invention, for example air, 10 nitrogen, oxygen, hydrogen, nitrous oxide, carbon dioxide, helium, argon, sulphur hexafluoride and low molecular weight optionally fluorinated hydrocarbons such as methane, acetylene or carbon tetrafluoride. The gas may be free within the microbubble, advantageously 15 in the form of a gas-filled "microballoon" since the echogenicity of such products may be enhanced by virtue of their relatively flexible nature. Alternatively the gas may be trapped or entrained within a containing substance. The term "gas" as used herein includes any 20 substances in gaseous form at 37°C.

Gas precursors include carbonates and bicarbonates, e.g. sodium or ammonium bicarbonate and aminomalonate esters. The term "gas precursor" as used herein also 25 embraces substances such as volatile hydrocarbons which may initially be encapsulated but thereafter are partially or completely removed from the vesicles, e.g. by evaporation or freeze-drying, to be replaced by gas.

30 For applications in echocardiography, in order to permit free passage through the pulmonary system and to achieve resonance with the preferred imaging frequency of about 0.1-15 MHz, it may be convenient to employ microbubbles having an average size of 0.1-10 μm , e.g. 35 1-7 μm . Substantially larger bubbles, e.g. with average sizes of up to 500 μm , may however be useful in other applications, for example gastrointestinal imaging or

- 5 -

investigations of the uterus or Fallopian tubes.

If desired the microbubbles may incorporate particulate stabilisers, for example inorganic materials such as silica or iron oxide which are only partially wetted by the solvent system employed, e.g. having a particle size of 1-500 nm. Colloidal silica having a particle size of 5-50 nm may advantageously be employed for this purpose.

10

Polymer systems which may be employed in the contrast agents of the invention include carbohydrates such as dextrans and starches, chitin, chitosan, carboxymethylchitosan, alginate, hyaluronic acid, polyacrylamides, polycyanoacrylates, hydroxyalkylpolycyanoacrylates, polyhydroxy acids such as polylactic acids, polyhydroxybutyrates, polyglycolic acids, polylactide-glycolides, polyorthoesters, polyanhydrides, polyurethanes, polyester imides, polyimides, polyacetals, poly-epsilon-caprolactones, polydioxanones, polyaminotriazoles, poly(amide-enamines), poly(amide-urethanes), polyphosphazenes, polyvinyl alcohols, organo-polysiloxanes, poly(enol-ketones) and copolymers of these materials, modified as necessary to introduce hydrophilic or lipophilic moieties.

The microbubbles according to the invention may be prepared by forming a fluid dispersion of vesicles comprising a gas or gas precursor encapsulated by amphiphilic material followed by crosslinking or polymerisation of the amphiphilic material.

The vesicles will normally comprise a substantially spherical monolayer or multilayer of the amphiphilic material. The hydrophilic moieties of the amphiphiles will be physically associated to form a contiguous layer

- 6 -

while the lipophilic moieties will also form a layer which may be inside or outside the hydrophilic layer. In bilayers, two layers of the amphiphilic material may be superimposed; thus, for example, a first layer of 5 amphiphilic material may form in which the lipophilic groups are on the outside. A second layer of amphiphilic material may then overlay the first layer with the lipophilic groups adjacent to the lipophilic groups of the first layer and the hydrophilic groups on 10 the outside. Similarly, a bilayer may have the lipophilic groups on the outside and inside and the hydrophilic groups sandwiched between.

Where the fluid in which the vesicles are dispersed 15 is polar, for example aqueous, the hydrophilic groups of the vesicles will tend to be on the outside of the micelles and the lipophilic groups will be on the inside forming a monolayer. On the other hand, if the dispersing fluid is apolar, the lipophilic groups will 20 be on the outside, particularly if the encapsulated material is hydrophilic, e.g. a gas precursor or a solid material containing absorbed or entrained gas, possible in association with a polar liquid. Bilayers may form when the encapsulated material is of the same type, i.e. 25 hydrophilic or lipophilic, as the dispersing fluid.

The amphiphiles used in accordance with the present invention will carry functional groups permitting cross-linking or polymerisation. These may in some instances 30 be groups imparting hydrophilic or lipophilic character or they may be independent of the amphiphilic groupings.

The amphipiles may be considered in three categories:

35

1. The amphiphiles may carry at least two simple reactive groups such as hydroxyl, amino or carboxyl

- 7 -

groups which are capable of reacting with polyvalent reactive monomers or preformed polymers. For example, if the amphiphile carries two hydroxyl groups (in the hydrophilic moiety), a dicarboxylic acid such as suberic acid may be reacted with the vesicles after encapsulation of the gas or gas precursor to provide a crosslinked or polymerised structure. Diamino-amphiphiles may similarly be reacted with dicarboxylic acids while dicarboxylic amphiphiles may be reacted with diamines or diols. Additional crosslinking may be provided by trifunctional reagents. A catalyst will normally be present to assist reaction.

The crosslinking agent may itself be amphiphilic so that the vesicle will form with the lipophilic and hydrophilic groups of the first amphiphile and the amphiphilic crosslinking agent in alignment, whereupon crosslinking between the reactive functional groups may be initiated.

As indicated above, it is particularly advantageous for the polymerised or crosslinked amphiphile to be biodegradable, especially into relatively simple water soluble units. In the case of the ester and amide bonds referred to above, esterase and amidase enzymes will commonly be available in the vascular system and can degrade the encapsulating material back to separate amphiphile molecules and the diamine, diol or diacid reagents which under physiological conditions will not recombine.

If desired, even more biolabile crosslinking groups such as carbonate ester groups may be introduced e.g. using orthoester crosslinking agents. Another useful class of crosslinking agents have the formula (I)



- 8 -

- (where Y and Z, which may be the same or different, are -O-, -S- or -NR³-; R¹ and R², which may be the same or different, are hydrogen atoms or carbon-attached monovalent organic groups or together represent a carbon-attached divalent organic group; R³ is a hydrogen atom or an organic group; the symbols n, which may be the same or different, are zero or 1; R⁸ and R⁹, which may be the same or different are divalent organic groups, for example alkylene or alkylidene groups having 1-12 carbon atoms; and A¹ and A² are functional groups, for example reactive with hydroxyl, amino or carboxyl groups), since the crosslinking groups so introduced contain units of formula



- (where Y, Z, each n, R¹ and R² are as defined above) which are particularly readily degraded by common esterases, while exhibiting stability in the absence of enzymes.

- R¹, R² and R³ may each be a hydrocarbyl or heterocyclic group, for example having 1-20 carbon atoms, e.g. an alkyl or alkenyl group (preferably having up to 10 carbon atoms), a cycloalkyl group (preferably having up to 10 carbon atoms), an aralkyl group (preferably having up to 20 carbon atoms), an acyl group (preferably having up to 20 carbon atoms) or a heterocyclic group having up to 20 carbon atoms and one or more heteroatoms selected from O, S and N; such a hydrocarbyl or heterocyclic grouping may carry one or more functional groups such as halogen atoms or groups of the formulae -NR⁴R⁵, -CONR⁴R⁵, -OR⁶, -SR⁶ and -COOR⁷, where R⁴ and R⁵, which may be the same or different, are hydrogen atoms, acyl groups or hydrocarbyl groups as defined for R¹ and R²; R⁶ is a hydrogen atom or an acyl

- 9 -

- group or a group as defined for R¹ or R² and R⁷ is a hydrogen atom or a group as defined for R¹ or R²; where R¹ and R² represent a divalent grouping, this may for example be an alkylene or alkenylene group (preferably having up to 10 carbon atoms) which may carry one or more functional groups as defined above. In general R¹ and R² are preferably hydrogen or small groups such as C₁₋₄ alkyl groups.
- 10 2. The amphiphile may contain polymerisable groupings which can be caused to polymerise after vesicle formation. Such polymerisable groupings may, for example, include unsaturated lipophilic chains, e.g. alkenyl or alkynyl groupings containing up to 50 carbon atoms, for example 10-30 carbon atoms, such as oleyl or linoleyl groups or groups containing diacetylene, acryloyl or methacryloyl groupings. Polymerisation of such groupings will, in general, yield hydrocarbon backbone polymers the backbones of which are not readily biodegradable, although such polymers may be designed so that the backbone residue resulting from biodegradation is water-soluble, e.g. by virtue of the presence of hydrophilic substituents such as carboxyl or hydroxyl groups, to enhance its dispersibility. The chain length 20 of such polymers is in general preferably such that their molecular weight does not exceed 40,000.

Where a greater degree of biodegradability is required, it may be preferable to avoid formation of polymeric hydrocarbon chains which cannot readily be degraded and to effect polymerisation or crosslinking exclusively through biodegradable groups such as ester, carbonate, carbamate, amide or imide bonds of the type referred to above. In general, the functional groups 30 leading to such bonds will be hydrophilic and thus lead to crosslinking between the hydrophilic parts of the amphiphiles.

- 10 -

However, polymerisation of lipophilic hydrocarbon chains may be used to yield a biodegradable polymer if the amphiphile comprises a biodegradable hydrophilic moiety carrying two such chains; where the lipophilic 5 chains of adjacent amphiphile molecules become crosslinked, e.g. via unsaturated carbon-carbon bonds, the extended lipophilic groupings so formed will be separated by the biodegradable hydrophilic groups; on biodegradation, the polymeric structure will thus break 10 up into relatively small lipophilic molecules carrying the residues of the degraded hydrophilic moieties.

3. A soluble amphiphilic polymer carrying appropriate functional groups may be further polymerised or 15 crosslinked after vesicle formation. Such substances include polyamino acids and carbohydrates carrying lipophilic groups, as well as low molecular weight polyesters, polyamides etc carrying appropriate groups providing amphiphilic character. Thus, for example, 20 hydrophilic polymers, such as those listed above, may be provided with lipophilic chains, e.g. C₁₀₋₃₀ alkyl, alkenyl or alkynyl groups, to provide suitable amphiphiles for use in accordance with the invention. Chemical methods for the attachment of such lipophilic 25 chains include partial esterification of the hydroxyl groups of polyhydroxy acids, salt formation of anionic surfactants on the amino groups of chitosan or covalent derivatisation of such groups, and attachment of hydrophobic groups to carbohydrates or cyclodextrins by 30 way of ester bonds.

The soluble polymer for further polymerisation may also be an amphiphile polymerised or crosslinked in accordance with (1) or (2) above.

35

Polymerisable or crosslinkable amphiphiles which may be used in accordance with the invention thus

- 11 -

include compounds of the general formula (II).



5 where X is an anionic, cationic or non-ionic hydrophilic moiety;

R¹⁰ is a lipophilic group;

B is a group capable of polymerisation or cross-linking;

10 p and q are integers; and

r is zero or, when neither X or R¹⁰ is capable of polymerisation or crosslinking, is an integer.

15 The groups X and R¹⁰ may be joined in various ways.

Thus, for example, a hydrophilic group X may carry one or several lipophilic groups R¹⁰ or a lipophilic group R¹⁰ may carry one or several hydrophilic groups X. One or more hydrophilic groups X may also join separate

20 lipophilic groups R¹⁰ as long as the amphiphile can adopt a configuration in which the hydrophilic and lipophilic moieties of adjacent molecules are aligned.

Similarly, the group(s) B (where present) may be attached to one or more of the groups X and R¹⁰.

25 To provide or enhance biodegradability, one or more biodegradable groupings W may connect the groups X, R¹⁰ and B.

30

The group X may, for example, be a quaternary ammonium grouping -N(R¹¹)₃V where the groups R¹¹ (which may be the same or different) may be, for example, alkyl, aralkyl or aryl groups containing, for example, up to 20 carbon atoms, and V is an anion. It will be appreciated that one or more of the groups R¹¹ may be a lipophilic group R¹⁰.

- 12 -

Other useful hydrophilic groups X include, hydroxyl, carboxylate, amide, phosphate, sulphate and sulphonate groups. Further examples of hydrophilic groups X include:

5

- $\text{O} \cdot \text{CH}_2 \cdot \text{CH}_2 \cdot \text{N}^+(\text{CH}_3)_3$ (choline)
- $\text{O} \cdot \text{CH}_2 \cdot \text{CH}_2 \cdot \text{N}^+\text{H}_3$ (ethanolamine)
- $\text{O} \cdot \text{CH}(\text{NH}_3^+) \cdot \text{COO}^-$ (serine)
- $\text{O} \cdot \text{CH}_2 \cdot \text{CH}(\text{OH}) \cdot \text{CH}_2\text{OH}$ (glycerol)
- hexoses and pentoses such as inositol.

10

The group R^{10} may, for example, be a saturated or unsaturated, straight or branched hydrocarbon chain, which may contain, for example, 6-50 carbon atoms and 15 may be interrupted by one or more biodegradable groups W and may carry one or more functional groups permitting chains R^{10} on adjacent amphiphiles to crosslink to form a biodegradable group. Useful groups R^{10} include oleyl and linoleyl groups and chains containing diacetylene 20 groupings.

The group(s) B may be, for example, orthoester groups which form carbonate ester linkages with hydroxyl groups, or hydroxyacid groups (or separate hydroxyl and 25 carboxyl groups) which form ester linkages.


It will be appreciated that the hydrophilic group X may comprise a moiety which is not itself directly responsible for hydrophilic properties, as in the case 30 of a group R^{11} of a quaternary ammonium grouping as defined above, which may for example be a lower alkyl group too small to impart lipophilic character; such groups may also form part of the connection between the groups X and R^{10} . In other words, there may be 35 transitional regions between groups X and R^{10} which are not strictly either lipophilic or hydrophilic in themselves but can be regarded as part of either X or

- 13 -

R¹⁰.

Thus, in a special case of the amphiphiles of formula (II), the groups X, R¹⁰ and B may be attached to 5 a preformed polymer which may be regarded as part of X or of R¹⁰ according to its chemical and physical character. Such a polymer may be a known hydrophilic polymer on to which lipophilic groups (as discussed above) have been attached, or a lipophilic polymer, e.g. 10 a polyolefin, carrying hydrophilic groups. Alternatively, such a polymer may be obtained by partial polymerisation of an amphiphile of formula (II). In all such cases, the preformed polymer should be sufficiently soluble to permit vesicle formation and should be so 15 functionalised as to permit covalent, ionic or coordinate crosslinking to stabilise the vesicles.

Particularly useful monomeric amphiphiles include 20 cyanoacrylate esters carrying lipophilic esterifying groups (which may also have hydrophilic moieties). Thus, for example, US 4329332 describes the micellar polymerisation of lower alkyl cyanoacrylates, a technique which may be extendable to the polymerisation 25 of acrylates of the formula CH₂=C(CN).CO.O.(C₆₋₂₀ aliphatic). Similarly, a di-acrylate of the formula



has been used by Ping et al (Int. J. Pharm., 61 (1990) 30 79-84). Corresponding cyanoacrylates may also be used.

Amphiphilic materials of use in accordance with the invention include the following classes of substances derivatised with lipophilic groups:-


- 35 lecithin derivatives,
polyglycerol,
polyoxyethylene glycol and ethers thereof,

- 14 -


polyoxyethylene derivatives of steroids,
glycosides,
galactosides,
hydroxyacids or polyhydroxyacids (including
5 carboxylic, phosphonic, sulphonic and sulphinic
acids),
carbohydrates and derivatives thereof,
aminoalcohols and derivatives thereof,
cyanoacrylates,
10 acrylamides, and
hydroxyamides.

Polymerisable Amphiphiles

15 A number of classes of useful polymerisable
amphiphiles are listed below:



20 where B_1 and B_2 may be



(where n is an integer e.g. 9, 12 or 13) as
25 described in WO 85/04326. Such compounds can be made by
conventional phospholipid chemistry as described in
Hirth et al (Helv.Chem.Acta 40, 1957, 1928) and Pfeiffer
et al (J.Org.Chem. 35, 1970, 221).

30 Such compounds may thus be prepared by procedures
described in EP-A-0032622. The zwitterionic group may
be introduced by subjecting the appropriate phosphonic
or phosphinic acid or an esterifiable derivative thereof
to reaction with glycerol or an esterifiable derivative
35 thereof. The groups B_1 and B_2 may be introduced into the
molecule by esterification using the carboxylic acid of
 B_1 and B_2 or an ester-forming derivative thereof. These

- 15 -

reactions can be carried out between the glycerol or derivatives thereof on the one hand, and the carboxylic acid and the phosphorus ester on the other, either simultaneously or optionally in steps. Other known methods for the synthesis may equally well be used.

Polymerisation of these compounds may, for example, be obtained by irradiation at 254 nm using a xenon lamp after formation of gas containing liposomes or formation of monolayers of the amphiphiles at the gas/liquid interface.


2. Phospholipids such as phosphodiglycerides and sphingolipids carrying polymerisable groups.

15







3. Unsaturated oils having hydrophilic groups such as corn oil, sunflower seed oil, soybean oil, safflower oil, peanut oil, cottonseed oil and olive oil.



20 4. Saturated and unsaturated fatty acid derivatives with hydroxyl groups, for example castor oil and ergot oil which are triglycerides of d-12-hydroxyoleic acid.

25 5. Compounds as described in "Polymerised Liposomes" (Technical Insights Inc 1988) and Hub et al (J. Macromol.Sci.Chem. A15, (5), 1981, 701-715). These may have the structures:




- 16 -





6. Compounds of the formula:

25



where L and M may be -O-, -S- or -NR¹²- (where R¹² is H or an alkyl group), for example the compounds in which

30

$L = M = -O-$; $L = -O-, M = -N(CH_3)-$; $L = -NH-, M = -O-$;

$L = -O-$, $M = -N(CH_3)_2-$ \bar{Br} and

$$L = -O-, \quad M = -N(CH_2 \cdot CH_2 \cdot SO_3H) -$$


35

Such compounds may be prepared by reacting a reactive derivative of hexacosane-10,12-diynoic acid (e.g. the acid chloride) with the appropriate compound $(HLCH_2CH_2)_2M$ in dry chloroform at $0^\circ C$ in the presence of pyridine, if necessary followed by quaternisation.


Synthesis of hexacosane-10,12-dienoic acid is described by Singh et al (Polym. Prep. : Am. Chem. Soc. Div. Polym. Chem; 26 (2), 1985, 184-5). The acid chloride may be prepared by reaction with oxalylchloride.

- 18 -

7. Compounds as described by Paleos (Chem.Soc.Rev. 14, 1985, 45-67), for example of the following structures:

5 $n\text{-C}_{18}\text{H}_{17}$  2 Br^-

10




|



|



15




|




20




|



|



25




|








30



35





- 19 -



35

- 20 -



15 8. Esters of α -amino fatty acids which may be self condensed as described by Folda et al (Rapid.Commun. 3, 1982, 167-174) e.g. methyl 2-aminoctadecanoate, docosanyl 2-aminoctadecanoate, methyl 2-aminohexcosanoate and docosanyl 2-amino-hexacosanoate.

20 These esters of the long chain amino acids may be synthesized from the saturated carboxylic acids by α -bromination using the Hell-Volhard-Zelinsky reaction. The resulting α -bromo acids are converted to the corresponding amino acid by the method of Cheronis *et al* (J.Org.Chem. 6 (1949) 349). The methyl esters of the amino acid hydrochlorides are prepared by passing dry HCl-gas through a suspension of the amino acid in refluxing methanol. The docosanyl ester of the amino acid hydrochlorides are synthesized by passing dry HCl-gas through a 1:1 mixture of amino acid and docosanol at 110°C. The ester hydrochlorides are then suspended in dry chloroform and converted to the free amine by passing dry ammonia through the suspension.

35 9. Long chain esters of sulphosuccinic acid carrying polymerisable functions.

- 21 -

10. Long chain esters of pyridinium dicarboxylic acids (e.g. 3,5-dicarboxy 1-methyl pyridinium iodide) carrying polymerisable functions.
- 5 11. Iodinated X-ray contrast agents carrying long chain ether or ester groups having polymerisable functions. Thus, for example, an X-ray contrast agent derived from iothalamic acid may have multiple N-dihydroxyalkyl groups one or two of which may be esterified with long
- 10 chain fatty acids. Thus, for example, iohexol may be partially protected by forming an acetonide derivative of two of the three dehydroxy alkyl groups, followed by reaction with an activated fatty acid, e.g. the acid chloride, and deprotection to remove the acetonide
- 15 groups. Such an amphiphile may readily be cross-linked by reaction with a dicarboxylic acid after vesicle formation.
- 20 12. Di-fatty acid esters of sorbitan. The multiple free hydroxyl groups which are present permit cross-linking by diacids. Alternatively, the esterifying fatty acid groups may be unsaturated to permit olefinic addition polymerisation.
- 25 13. Diesters of the formula
- $R^{13}.CO.O.CH(R^{14}).O.CO.R^{13}$
- 30 where R^{14} is a hydrophilic group and each R^{13} is a lipophilic group, at least one of R^{13} and R^{14} carrying a polymerisable group and/or functional groups permitting crosslinking. Such compounds may be synthesised by reaction of a dihalide of the formula $R^{14}.CH.Hal_2$ with a salt of an acid $R^{13}.COOH$. They are particularly readily
- 35 biodegradable.

- 22 -

It may also be beneficial to include in the encapsulating material one or more further amphiphiles such as cholesterol which are not bonded or polymerised but serve to improve the stability and/or flexibility of 5 the microbubbles.

As indicated above the microbubbles may be stabilised by incorporation of particulate material 10 together with the encapsulated gas. Such particles include, for example, silica and iron oxide. The preferred particle size for such stabilising particles is in the range 1 to 500 nm, depending on the size of the microbubbles. The particles should be such that 15 they are only partially wetted by the fluid medium used to disperse the micelles, i.e. the contact angle between the material of the particles and the fluid should be about 90 degrees.

20 The stabilising particles may carry functional groups which will interact with the amphiphiles to form covalent or other linkages. Particles of the polymerised amphiphiles of formula (II) may be useful in this context. Colloidal silica particles may have a 25 particle size in the range 5-50 nm and may carry silanol groups on the surface which are capable of interaction with the amphiphile by hydrogen bonding or by forming covalent bonds.

30 The amphiphiles may stabilize the gas or gas precursor by forming a monolayer at the interface between the liquid medium and the gas or gas precursor system, or by forming vesicles consisting of one or more layers containing the gas or gas precursor. The liquid 35 medium may be water or an any non-aqueous liquid with polar, protic, aprotic or apolar characteristics.

- 23 -

The stabilisation of the system by monolayers or multilayers or the formation of the vesicles may be activated, as fully described in the literature, by sonication or even shaking of the amphiphilic material
5 mixture in the appropriate medium, or the vesicles may be formed by any conventional liposome/vesicle-forming principle.

10 The amphiphiles may form conventional micelles, or inverse micelles when using an apolar non-aqueous medium. The stabilized systems may be dried or freeze-dried or the non-aqueous phase may be evaporated. The resulting dried system may be resuspended in any physiological acceptable solvent such a saline or
15 phosphate buffer, optionally using a suspending or emulsifying agent.

20 The methods of polymerization used for the stabilisation of the vesicles, are well established methods in polymer chemistry, i.e. as described in "Comprehensive Polymer Science", Vol 1-7, Pergamon Press, Oxford 1989, or "Methoden der Organischen Chemie", Houben-Weyl, Makromolekulare Stoffe Band E20/1-3, Georg Thieme Verlag, Stuttgart 1987. Examples of
25 suitable methods may be chain polymerization methods such as ionic or radical polymerisation or metal catalysed polymerisation, or the systems may polymerize spontaneously by step polymerisation when monolayers or vesicles are formed. Initiators may be UV-irradiation or simple pH-change, or radical initiators.
30 Particularly interesting here may be encapsulation of a substance which, by slight increase in temperature develops a gas, and simultaneously generates free radicals which initiates polymerisation of the surrounding shell. Such a substance is described in
35 "Comprehensive Polymer Science", Vol 3, Pergamon Press, Oxford 1989, p.p. 99, i.e. azo-bis-isobutyronitrile

- 24 -

(AIBN), which by UV-irradiation, or by warming to 40°C starts generating N₂ while generating two molecules of cyano-isopropyl radicals which may initiate polymerisation or rapidly pair. Polymerisation of 5 amphiphiles containing unsaturated groupings may also be initiated by sonication (see Price et al., Brit. Polym. J. 23 (1990), 63-66), e.g. when this is used to generate a gas-in-liquid emulsion as described in greater detail hereafter.

10

A gas entrapped system may be obtained by using a gas precursor or the gas itself may be entrapped. The gas may be entrapped into the amphiphile mixture simply by vigorously shaking the mixture in the presence of 15 air, i.e. creating a gas-in-liquid emulsions as described in US 4684479. Another well established method, described e.g. in US 4774958 for creating a gas containing bubble is by sonication of the mixture in the presence of air. Another well known method comprises 20 passing gas through a syringe into a mixture of amphiphile and liquid. As described in US 3900420 the microgas-emulsion may be created by using an apparatus for introducing gas rapidly into a fast-flowing liquid. A region of low pressure is created in a liquid 25 containing the amphiphile. The gas is then introduced to the region of low pressure and the gas-in- liquid system is obtained by pumping the liquid through the system.

30

By using the principle of electrolysis it is possible to generate the gas to be entrapped directly in a container containing the amphiphiles. The electrolytes necessary for the electrolysis may even help to further stabilize the amphiphiles to make the 35 polymerisation possible. An aqueous solution containing electrolytes may generate hydrogen gas at the cathode and oxygen at the anode. The electrodes may be

- 25 -

separated by a salt bridge. On adding hydrazine nitrogen gas may be generated at the anode. Using the Kolbe reaction, one may also generate CO₂ from carboxylic acids using electrolysis.

5

As described above, gas entrapped vesicles may be obtained by forming liposomes or vesicles consisting of one or more bilayers. These vesicles may be formed at elevated pressure conditions in such a way that the gas is entrapped in the vesicles.

10 It is also possible to form a liquid-liquid (e.g. oil-in-water emulsion in the presence of amphiphile systems as discussed above, e.g. by sonication, to form 15 liquid-containing vesicles which can then be polymerised. The polymerised vesicles may then be treated to remove the liquid (conveniently a volatile hydrocarbon) therefrom by evaporation, where the boiling point of the liquid is relatively low, or by extraction 20 with a low-boiling solvent which can itself be removed by evaporation. Evaporation of low-boiling liquid cores may also occur spontaneously during sonication. Where the liquid in the vesicles is water, it can be removed by freeze drying.

25

The following Examples are given by way of illustration only;

30 Bis-linoleyl-lecithin is commercially available from Lipids Products, Surrey, UK:-

Example 1

35 A saturated solution of the bis-linoleyl-lecithin in an aqueous medium is obtained by mixing 100 mg of the amphiphile in 100 ml of sterile, pyrogen free water. The saturated solution is filtered through a 0.45 µm

- 26 -

filter, and the resulting solution is sonicated for 1-10 minutes in the presence of air. During the sonication, air is entrapped into the solution and a gas-in-liquid emulsion is formed. Polymerization of the monolayer of 5 the amphiphile at the gas-liquid interphase is achieved by UV-irradiation of the solution at 254 μm using a xenon lamp, or by addition of a radical initiator.

The resulting product contains microspheres with 10 gas entrapped. The microspheres are separated from excess polymerised amphiphiles using a separating funnel. The resulting microspheres are resuspended in sterile, pyrogen-free saline, and filled into 10 ml vials. The product is produced using aseptic techniques 15 in a "clean room" (LAF-station) to obtain a sterile, pyrogen free product. The particle sizes of the microspheres are in the range of 0.5-10 μm .

Example 2

20 Example 1 is repeated using as polymerisable amphiphile the compound bis-(trieicoso-10,12-diynoyl) phosphatidyl choline (Hirth et al; Helv Chim Acta 40, 957, 1928).

25 Example 3

100 mg of bis-linoleyl-lecithin are dissolved in a mixture of chloroform/methanol. The mixture is poured into a round bottom flask, and the organic phase is 30 evaporated using a rotavapor in such a way that a thin film of the lecithin derivative is formed at the inner surface of the flask. 10 ml of sterile, pyrogen-free-free water are added and the lipids are dispersed in the solution by sonication at the air/liquid interphase for 35 5-15 minutes. Gas entrapped vesicles are formed, and the gas-containing microspheres are polymerised by UV-irradiation of the solution at 254 nm using a xenon-lamp

- 27 -

or by addition of a radical initiator under continuous stirring. Polymerised gas-entrapped vesicles are separated from excess polymerised amphiphiles using a separating funnel. The resulting vesicles are suspended
5 in sterile, pyrogen free saline and filtered to obtain a product which contains microspheres in the range of 0.5-5 µm. The product is produced using aseptic techniques in a "clean room" (LAF-station) to obtain a sterile, pyrogen free product. The final product is
10 filled into 10 ml vials.

Example 4

15 Example 3 is repeated using as polymerisable amphiphile the compound bis-(trieicoso-10,12-diynoyl) phosphatidyl choline (Hirth et al; Helv Chim Acta 40, 957, 1928).

Preparation of polymerisable amphiphiles

20 Example 5

Tetraethylene glycol mono-12-(methacryloyloxy)dodecanoate

12-(Methacryloyloxy)dodecanoic acid (Regen et al., J. Am. Chem. Soc. 1982, 104, 795) (2.75 g, 9.65 mmol) was dissolved in tetrahydrofuran (45 ml) and a solution of oxalyl chloride (2.1 ml, 24.2 mmol) in tetrahydrofuran (5 ml) was added dropwise. The mixture was stirred for 24 hours at room temperature, and then the solvent was
25 evaporated under reduced pressure. The residue was dissolved in tetrahydrofuran (25 ml) and added dropwise to a solution of tetraethylene glycol (1.88 g, 9.65 mmol) and pyridine (0.92g, 11.7 mmol) in tetrahydrofuran (35 ml). The mixture was stirred for 24 hours at room
30 temperature. The precipitated pyridinium salt was dissolved in tetrahydrofuran (25 ml) and added dropwise to a solution of tetraethylene glycol (1.88 g, 9.65 mmol) and pyridine (0.92g, 11.7 mmol) in tetrahydrofuran (35 ml). The mixture was stirred for 24 hours at room
35 temperature. The precipitated pyridinium salt was filtered off and the solvent evaporated.
Chromatographic purification on a silica gel column

- 28 -

(ethyl acetate) afforded 1.67 g (38%) of the title compound. ^1H NMR (60 MHz, CDCl_3): δ 1.3 (br s, 18H, $(\text{CH}_2)_9$), 1.95 (m, 3H, $\text{C}=\text{CCH}_3$), 2.1-2.6 (m, 2H, CH_2COO), 3.5-3.8 (m, 14H, $3\times\text{CH}_2\text{OCH}_2\text{CH}_2+\text{COOCH}_2\text{CH}_2$), 4.0-4.4 (m, 4H, COOCH_2), 5.52 (m, 1H, vinyl), 6.10 (m, 1H, vinyl).

Example 6

Polyethylene glycol (550) methyl ether

12-(methacryloyloxy)dodecanoate

10 12-(Methacryloyloxy)dodecanoic acid (1.90 g, 6.69 mmol) was dissolved in tetrahydrofuran (20 ml) and a solution of oxalyl chloride (2.12 g, 16.7 mmol) in tetrahydrofuran (10 ml) was added dropwise. The mixture was stirred for 24 hours at room temperature, and then the solvent was evaporated under reduced pressure. The residue was dissolved in tetrahydrofuran (10 ml) and added dropwise to a solution of polyethylene glycol (550) monomethyl ether (3.68 g, 6.69 mmol) and pyridine (0.53 g, 6.69 mmol) in tetrahydrofuran (25 ml). The mixture was stirred for 24 hours at room temperature. The precipitated pyridinium salt was filtered off and the solvent evaporated. Chromatographic purification on a silica gel column (chloroform) afforded 2.31 g (42.3%) of the title compound. ^1H NMR (60 MHz, CDCl_3): δ 1.3 (br s, 18H, $(\text{CH}_2)_9$), 1.95 (m, 3H, $\text{C}=\text{CCH}_3$), 2.1-2.5 (m, 2H, CH_2COO), 3.11 (s, 3H, CH_3O), 3.5-3.8 (m, 25H (average), $\text{CH}_2\text{OCH}_2\text{CH}_2+\text{COOCH}_2\text{CH}_2$), 3.9-4.4 (m, 4H, COOCH_2), 5.52 (m, 1H, vinyl), 6.10 (m, 1H, vinyl).

30

Example 7

Polyethylene glycol (2000) methyl ether

12-(methacryloyloxy)dodecanoate

35 12-(Methacryloyloxy)dodecanoic acid (2.84 g, 0.01 mol) in tetrahydrofuran (20 ml) was reacted with oxalyl chloride (3.0 g, 0.024 mol) to obtain the corresponding

- 29 -

acid chloride. This acid chloride (3.0 g, 0.01 mol) dissolved in anhydrous tetrahydrofuran (10 ml) was added dropwise to a mixture of polyethylene glycol (2000) monomethyl ether (20.0 g, 0.01 mol) and anhydrous 5 pyridine (0.83 g, 0.01 mol) in anhydrous tetrahydrofuran (300 ml). The mixture was stirred for 48 hours at room temperature. The resulting liquid was purified by flash chromatography (silica gel/ethyl acetate) to give 16.5 g (75%) of the title compound. ^1H NMR (60 MHz, CDCl_3): δ 10 1.20 (s, 18H, CH_2), 2.15 (m, 2H, CH_2COOH), 3.5 (s, 3H, CH_3O), 3.6 (s, 180H, $90\text{xCH}_2\text{O}$), 4.0 (m, 4H, 2x COOCH_2), 5.7-6.0 (m, 3H, $\text{CH}_2=$ and =CH).

Example 8

15 a) 16-(Methacryloyloxy)hexadecanoic acid

16-Hydroxyhexadecanoic acid (6.81 g, 25.0 mmol) was dissolved in tetrahydrofuran (150 ml) and the solution was cooled to 0°C before adding pyridine (2.73 g, 34.5 20 mmol). Methacryloyl chloride (2.61 g, 25.0 mmol) was dissolved in tetrahydrofuran (75 ml) and added dropwise. The mixture was stirred for 1 hour at 0°C, and then at room temperature for 24 hours. The solvent was removed under reduced pressure (room temperature), the residue 25 suspended in ether (100 ml) and the mixture washed with distilled water. The ether layer was dried (MgSO_4) and the ether evaporated. Chromatographic purification on a silica gel column (1:2 ethyl acetate/hexane) afforded 5.0 g (64%) of the title compound. ^1H NMR (60 MHz, CDCl_3): δ 1.3 (br s, 26H, $(\text{CH}_2)_{13}$), 1.95 (m, 3H, $\text{C}=\text{CCH}_3$), 30 2.1-2.6 (m, 2H, CH_2COO), 4.0-4.4 (m, 2H, COOCH_2), 5.52 (m, 1H, vinyl), 6.10 (m, 1H, vinyl).

35 b) Tetraethylene glycol mono-
16-(methacryloyloxy)hexadecanoate

16-(Methacryloyloxy)hexadecanoic acid (2.05 g, 6.57

- 30 -

mmol) was dissolved in tetrahydrofuran (25 ml) and a solution of oxalyl chloride (1.4 ml, 16.5 mmol) in tetrahydrofuran (10 ml) was added dropwise. The mixture was stirred for 24 hours at room temperature, and then 5 the solvent was evaporated under reduced pressure. The residue was dissolved in tetrahydrofuran (10 ml) and added dropwise to a solution of tetraethylene glycol (1.07 g, 5.50 mmol) and pyridine (0.44 g, 5.50 mmol) in tetrahydrofuran (25 ml). The mixture was stirred for 24 10 hours at room temperature. The precipitated pyridinium salt was filtered off and the solvent evaporated. Chromatographic purification on a silica gel column (2:1 ethyl acetate/hexane) afforded 0.84 g (30%) of the title compound. ^1H NMR (60 MHz, CDCl_3): δ 1.3 (br s, 26H, 15 $(\text{CH}_2)_{13}$), 1.95 (m, 3H, $\text{C}=\text{CCH}_3$), 2.1-2.6 (m, 2H, CH_2COO), 3.5-3.8 (m, 14H, $3x\text{CH}_2\text{OCH}_2\text{CH}_2+\text{COOCH}_2\text{CH}_2$), 4.0-4.4 (m, 4H, COOCH_2), 5.52 (m, 1H, vinyl), 6.10 (m, 1H, vinyl).

Example 9

20 Polyethylene glycol (350) methyl ether
16-(methacryloyloxy)hexadecanoate

The product was prepared from 16-(methacryloyloxy)- 25 hexadecanoic acid (prepared as described in Example 8(a)), and polyethylene glycol (350) monomethyl ether using the procedure given in Example 6.

Example 10

a) 12-(Acryloyloxy)dodecanoic acid
30 12-Hydroxydodecanoic acid (5.0 g, 0.023 mol) dissolved in tetrahydrofuran (100 ml) and pyridine (2.16 g, 0.027 mol) was cooled to 0°C. Acryloyl chloride (3.15 g, 0.023 mol) in tetrahydrofuran (75 ml) was then added 35 dropwise to the solution. The mixture was stirred for 5 hours at 0°C then stirred overnight at room temperature. The precipitated pyridinium salt was filtered off and

- 31 -

the solvent removed under vacuum. The resulting liquid was purified by flash chromatography (silica gel/chloroform) to give 2.5 g (40%) of the title compound.
5 ^1H NMR (60 MHz, CDCl_3): δ 1.20 (s, 18H, CH_2), 2.15 (m, 2H, CH_2COOH), 4.0 (m, 2H, COOCH_2), 5.7-6.0 (m, 3H, $\text{CH}_2=$ and =CH).

b) Tetraethylene glycol mono- 12-(acryloyloxy)dodecanoate

10 12-Acryloyloxydodecanoic acid (2.00 g, 0.007 mol) in diethyl ether (20 ml) was reacted with oxalyl chloride (2.40 g, 0.019 mol) to obtain the corresponding acid chloride. This acid chloride (1.80 g, 0.006 mol)
15 dissolved in anhydrous chloroform (10 ml) was added dropwise to a mixture of tetraethylene glycol (1.20 g, 0.006 mol) and anhydrous pyridine (0.50 g, 0.006 mol) in anhydrous chloroform (30 ml). The mixture was stirred overnight at room temperature. The resulting liquid was
20 purified by flash chromatography (silica gel/ethyl acetate) to give 1.10 g (40%) of the title compound as a colourless oil. ^1H NMR (60 MHz, CDCl_3): δ 1.20 (s, 18H, CH_2), 2.15 (m, 2H, CH_2COOH), 3.50 (s, 3H, CH_3O), 3.6 (s, 14H, 7 \times CH_2O), 4.0 (m, 5H, 2 \times COOCH_2 and OH), 5.7-6.0 (m, 3H, $\text{CH}_2=$ and =CH).

Example 11

Tetraethylene glycol mono- 10,12-tricosadiynoate

30 10,12-Tricosadiynoic acid (2.50 g, 0.007 mol) in tetrahydrofuran (30 ml) was reacted with oxalyl chloride (2.25 g, 0.017 mol) to obtain the corresponding acid chloride. This acid chloride (2.45 g, 0.007 mol) dissolved in anhydrous tetrahydrofuran (10 ml) was added
35 dropwise to a mixture of tetraethylene glycol (1.32 g, 0.007 mol) and anhydrous pyridine (0.83 g, 0.01 mol) in anhydrous tetrahydrofuran (40 ml). The mixture was

- 32 -

stirred overnight at room temperature. The precipitated pyridinium salt was filtered off and the solvent removed under vacuum. The resulting liquid was purified by flash chromatography (silica gel/ethyl acetate) to give 5 1.50 g (41%) of the title compound as a colourless oil.
¹H NMR (60 MHz, CDCl₃): δ 0.88 (m, 3H, CH₃CH₂), 1.30 (m, 28H, CH₂), 2.20 (m, 6H, CH₂), 3.65 (s, 14H, 7xCH₂O), 4.20 (m, 2H, CH₂CO).

10 Example 12

Polyethylene glycol (550) methyl ether

10,12-tricosadiynoate

15 10,12-Tricosadiynoic acid (2.50 g, 0.007 mol) in tetrahydrofuran (30 ml) was reacted with oxalyl chloride (2.25 g, 0.017 mol) to obtain the corresponding acid chloride. This acid chloride (2.45 g, 0.007 mol) dissolved in anhydrous tetrahydrofuran (10 ml) was added dropwise to a mixture of polyethylene glycol (550)
20 monomethyl ether (3.85 g, 0.007 mol) and anhydrous pyridine (0.83 g, 0.01 mol) in anhydrous tetrahydrofuran (30 ml). The mixture was stirred overnight at room temperature. The precipitated pyridinium salt was filtered off and the solvent removed under vacuum. The resulting liquid was purified by flash chromatography
25 (silica gel/ethyl acetate) to give 2.72 g (41%) of the title compound as a colourless oil. ¹H NMR (60 MHz, CDCl₃): δ 0.88 (m, 3H, CH₃CH₂), 1.30 (m, 28H, CH₂), 2.20 (m, 6H, CH₂), 3.65 (s, 48H, 24xCH₂CO), 3.50 (s, 3H, CH₃O), 4.20 (m, 2H, CH₂CO).

Example 13

a) Methyl 10,12-tricosadiynoate

35 10,12-Tricosadiynoic acid (3.0 g, 0.0084 mol), methanol (15 ml) and concentrated sulfuric acid (0.8 ml) were heated to reflux and stirred for 1 hour. The cooled

- 33 -

mixture was taken up in ether (40 ml) and washed with 10% NaHCO₃ (20 ml) and water (20 ml), and the organic phase was dried (MgSO₄). Evaporation of the solvent gave 2.68 g (74%) of the title compound. ¹H NMR (60 MHz, CDCl₃): δ 0.98 (m, 3H, CH₃CH₂), 1.28 (m, 28H, CH₂), 2.25 (m, 6H, CH₂), 3.70 (s, 3H, CH₃O).

b) N-(2',3'-Dihydroxypropyl)-10,12-tricosadiynamide

10 Methyl 10,12-tricosadiynoate (1.69 g, 4.67 mmol) was dissolved in methanol. 3-Amino-1,2-propanediol (0.509 g, 5.6 mmol) and sodium methoxide 2.5% solution in methanol (0.146 g, 3 mol%) was added. The mixture was refluxed for 3 hours and the solvent evaporated. The 15 crude product was recrystallized from chloroform. Yield: 1.00 g (51%). ¹H NMR (60 MHz, CDCl₃): δ 0.7-1.0 (m, 3H, CH₃CH₂), 1.3 (s, br, 28H, CH₂), 2.0-2.4 (m, 6H, CH₂), 3.3-3.8 (m, 5H, 2xCH₂ + CH (propanediol)), 6.0-6.3 (m, 1H, NH).

20

Example 14

N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-5-(tricosa-10,12-diynoylamino)isophthalamide

25 5-Amino,N,N'-bis(2,3-diacetoxypropyl)-2,4,6-triiodoisophthalamide (2.19 g, 2.5 mmol) and 10,12-tricosadiynoyl chloride (1.82 g, 5 mmol) were dissolved in 20 ml dichloromethane. The solution was stirred for 3 days at ambient temperature under a nitrogen atmosphere. TLC (ethyl acetate) indicated that the reaction was complete. The reaction mixture was evaporated and dissolved in a mixture of methanol (30 ml) and 1M sodium hydroxide solution (15 ml). After 1 hour TLC (methanol/chloroform) indicated that the 30 reaction was complete. The solution was neutralized with concentrated hydrochloric acid. The residue was dissolved in chloroform and filtered. The solvent was 35

- 34 -

removed and the reaction mixture was purified through silica gel with methanol/chloroform (1:3) to give the title compound. ^1H NMR (300 MHz, DMSO): δ 0.8 (CH_3 , t), 1.2-1.7 (17x CH_2 , m), 2.2-2.3 (2x CH_2 , t), 3.1-3.2 (2x CH_2NH , m), 3.3-3.5 (2x CH_2OH , m), 3.6-3.8 (2x CHOH), 4.4-4.7 (4xOH, m), 8.4-8.5 (2xCONH, m), 9.8 (2xArNHCO, s).

Example 15

10 N-(3',4',5'-Trihydroxy-6'-hydroxymethyltetrahydropyran-2'-yl)-10,12-tricosadiynamide

15 1-Amino-1-deoxy- β -D-galactose (180 mg, 1 mmol), 10,12-tricosadiynoic acid (350 mg, 1 mmol) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide were dissolved in 25 ml dry dimethylformamide and stirred at room temperature overnight. The solvent was removed in vacuo, the residue redissolved in chloroform/methanol (1:1), filtered and purified by straight phase chromatography 20 on a CHROMATOTRON. The relevant fractions were collected, concentrated in vacuo, and the product was characterised by NMR.

Example 16

25 6-(2',6'-Diaminohexanoylamino)-3,4,5-trihydroxytetrahydropyran-2-ylmethyl 10,12-tricosadiynoate

30 1-Amino-1-deoxy- β -D-galactose (180 mg, 1 mmol), and Fmoc-Lys(Boc)-OPfp (650 mg, 1 mmol) were dissolved in 4 ml dry dimethylformamide and stirred at room temperature overnight. The solvent was removed in vacuo, the residue was redissolved in acetonitrile/water (1:1), filtered and purified by reversed phase chromatography (Lobar RP8B, acetonitrile/water 50:50 and 65:35). The 35 relevant fractions were collected, concentrated in vacuo, and the product was characterised by NMR. The purified product (1 g, 1 mmol), 10,12-tricosadiynoic

- 35 -

acid (350 mg, 1 mmol) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide are dissolved in 10 ml dry dimethylformamide and stirred at room temperature overnight. The solvent is removed in vacuo, the residue
5 redissolved in chloroform/methanol (95:5), filtered and purified by straight phase chromatography on a CHROMATOTRON. The relevant fractions are collected, concentrated in vacuo, and the product is characterised by NMR. The protecting groups of the α - ϵ amino groups
10 are removed by standard reactions. Boc is removed by treatment with trifluoroacetic acid/methylene chloride for 30 minutes. The solvent is removed in vacuo. Fmoc is removed by treating the residue with 20% piperidine in dimethylformamide for 30 minutes, and the solvent is
15 removed in vacuo. The final product is purified by reversed phase chromatography (Lobar RP8B).

Example 17

(3,4,5,6-Tetrahydroxytetrahydropyran-2-ylmethyl)

20 10,12-tricosadiynoate

1,2;3,4-di-O-isopropylidene-D-galactopyranose (2.6 g, 10 mmol) and 10,12-tricosadiynoic acid (3.5 g, 10 mmol) were dissolved in 25 ml methylene chloride. 1-Ethyl-
25 3(3-dimethylaminopropyl)carbodiimide (2 g, >10 mmol) was added neat. The reaction mixture was stirred overnight at room temperature. The reaction mixture was diluted to 100 ml, extracted with water (2x25 ml), dried over MgSO₄ and the solvent was removed in vacuo. The crude
30 product was treated with trifluoroacetic acid (10 ml) at room temperature for 30 minutes, evaporated in vacuo, and purified by straight phase chromatography on a CHROMATOTRON, eluted with methanol/chloroform (5:95). The product was characterised by NMR.

Preparation of ultrasound contrast agentsExamples 18-41i) General preparative procedure

5 The polymerisable amphiphile was dissolved in a minimum of methanol and added to a mixture of water and a hydrocarbon. A comonomer and/or 2,2'-azobisisobutyronitrile (AIBN) dissolved in a minimum of methylene chloride were optionally added and nitrogen
10 was bubbled through the mixture for 1 minute, whereafter the mixture was sonicated under a nitrogen atmosphere using a LABSONIC 2000 apparatus, the sonication probe (length 127 mm, diameter 9.5 mm) being placed 2-3 cm below the surface of the mixture and the energy used
15 being "full scale" or "half scale" in the low position. The resulting emulsions were optionally irradiated with UV light under a nitrogen atmosphere or treated with a redox initiator comprising potassium metabisulphite (0.05 g, 0.22 mmol) in water (1 ml) and potassium peroxosulphate (0.0023 g, 3.3×10^{-3} mmol) in water (1 ml). The procedure was modified in Example 31 in that
20 AIBN was added and the mixture was then shaken by hand, whereafter a first portion of comonomer was added and sonication was effected while nitrogen gas was bubbled
25 through the mixture. A further portion of comonomer was then added and the resulting emulsion subjected to UV
irradiation.

30 The specific reaction conditions employed in each Example are set out in Table 1. Similar conditions, e.g. involving sonication for 5 minutes using the full scale setting and irradiating for 1 hour or adding the above-described redox initiator system and stirring carefully for 30 minutes, may be employed to treat the amphiphiles prepared in Examples 14-17.

Table 1 - Reaction conditions

Example No	Example in which amphiphile prepared and quantity used (g/mmol)	Volume of water (ml)	Hydrocarbon and volume (ml)	Comonomer and quantity (g/mmol)	Sonication level and duration (minutes)	Duration of UV irradiation (hours)	Redox system
18	0.039/0.084	50	PE-5	MM 0.018/0.18	-	fs-5	
5	5	50	IP-5	MM 0.018/0.18	-	hs-3	
19	0.037/0.080	50	IP-5	MM 0.18/1.8	0.20/1.21	fs-6	
20	0.383/0.83	500	IP-50	MM 0.09/0.9	0.02/0.12	fs-3	1.5
5	5	50	IP-5	MM 0.018/0.18	0.02/0.12	fs-3	1
21	0.042/0.091	50	PE-2.5	MM 0.180/1.80	0.200/1.20	fs-3	1
5	5	50	PE-5	MM 0.018/0.18	0.02/0.12	fs-4	
22	0.040/0.086	50	PE-50	MM 0.180/1.80	0.200/1.20	fs-8	
6	6	50	PE-50	MM 0.180/1.80	0.200/1.20	fs-8	1
23	0.053/0.065	500	PE-50	MM 0.180/1.80	0.200/1.20	fs-8	
6	6	500	PE-50	MM 0.180/1.80	0.200/1.20	fs-8	
24	0.530/0.65	500	PE-50	MM 0.180/1.80	0.200/1.20	fs-8	
6	6	500	PE-50	MM 0.180/1.80	0.200/1.20	fs-8	
25	0.500/0.61	500	PE-50	MM 0.180/1.80	0.200/1.20	fs-8	2.5
6	6	20	PE-2	MM 0.018/0.18	0.020/0.12	fs-3	
26	0.200/0.245	50	PE-25	MM 0.018/0.18	0.020/0.12	fs-3	
6	6	50	PE-1	MM 0.018/0.18	0.020/0.12	fs-3	
27	0.053/0.065	50	TO-5	ST 0.018/0.18	0.020/0.12	fs-3	
6	6	50	PE-5	ST 0.042/0.41	0.020/0.12	fs-3	1
28	0.054/0.066	50	PE-5	ST 0.042/0.41	0.020/0.12	fs-3	
29	0.054/0.066	50	PE-5	ST 0.042/0.41	0.020/0.12	fs-3	
30	0.056/0.069	50	PE-5	ST 0.042/0.41	0.020/0.12	fs-3	

Example No	Example In which amphiphile prepared and quantity used (g/mmol)	Volume of water (ml)	Hydrocarbon and volume (ml)	Comonomer and quantity (g/mmol)	Quantity of AlBN (g/mmol)	Sonication level and duration (minutes)	Duration of UV irradiation (hours)	Redox system
31	6 0.057/0.070	50	PE-5	ST 0.042/0.41 +0.089/0.95	0.020/0.12	fs-3	1	-
32	6 0.054/0.066	50	IP-5	MM 0.018/0.18	0.020/0.12	fs-6	-	-
33	7 0.193/0.090	50	PE-5	MM 0.018/0.18	0.020/0.12	fs-3	-	-
34	8(b) 0.042/0.081	50	IP-5	ST 0.018/0.18	0.020/0.12	hs-3	1	-
35	8(b) 0.046/0.089	50	PE-5	0.042/0.41	0.020/0.12	fs-3	-	-
36	9 0.052/0.077	50	PE-5	MM 0.018/0.18	0.020/0.12	fs-3	-	-
37	10(b) 0.036/0.08	50	PE-5	0.018/0.18	0.020/0.12	fs-3	1	-
38	11 0.047/0.09	50	PE-5	-	0.020/0.12	fs-6	-	-
39	11 0.080/0.15	50	PE-5	-	0.020/0.12	fs-3	1	-
40	12 0.057/0.06	50	PE-5	-	0.020/0.12	fs-3	-	✓*
41	13(b) 0.046/0.11	50	PE-5	-	0.020/0.12	fs-3	-	-

KEY - PE = petroleum ether (b.p. 40-60°C); IP = isopentane; TO = toluene; MM = methylmethacrylate; ST = styrene; fs = full scale; hs = half scale
 * Amount of potassium peroxosulphate reduced to 0.002g (0.003 mmol)

ii) Acoustic characterisation

The acoustic effects of the products of Examples 18-41 were investigated by measuring their ultrasonic transmission as a function of time, over a period of 90 seconds. The tests were performed on samples of emulsified material as formed immediately after sonication and, where appropriate, on the material after subjection to UV irradiation or redox initiation. In the case of Example 25 the sample removed after irradiation was retested after dilution with water (1:1). In the case of Example 31 a sample removed after the manual shaking was also tested. A 3.5 MHz broadband transducer was used in a pulse-reflection technique. All the readings were stable during the 90 seconds measurement period, so that a single value (in dB/cm) is sufficient to describe each 90 second measurement. In certain cases the measurements were repeated at time intervals to investigate further the stability of the ultrasound contrast agents. The results are presented in Table 2, the time intervals (in minutes from sonication) to acoustic characterisation are given in brackets for each reading.

- 40 -

Table 2
Acoustic characterisations

Example No.	Acoustic effect after sonication	Acoustic effect after UV irradiation/redox initiation
18	2.6 (0)	
19	3.7 (0)	
20	3.7 (0) 1.7 (90)	1.4 (90)
21	0.6 (0)	0 (60)
22	0.7 (0) 0.9 (5)	0.5 (60) 0 (120)
23	5.9 (0) 4.3 (104)	
24	6.0 (0)	4.1 (60)
25	4.4 (0) 4.2 (30) 2.9 (150)	
26	4.0 (0) 1.8 (60)	2.9 (150) diluted 2.8 (20, redox)
27	3.6 (0) 3.2 (10) 3.6 (60)	0.4 (60, UV) 2.9 (10) 2.3 (60) 0.6 (720)
28	0.9 (0)	
29	0.6 (0)	
30	5.7 (0) 4.1 (60) 3.2 (150)	3.2 (60) 2.6 (150)
31	2.5 (after shaking) 5.4 (0) 4.0 (60) 3.3 (150)	
		2.2 (60) 1.7 (150)
32	4.9 (0)	
33	5.5 (0) 4.7 (20) 3.5 (60) 3.1 (100)	
		2.4 (60)
34	2.2 (0)	0 (60)
35	1.1 (0)	
36	2.1 (0)	
37	1.7 (0)	0 (60)
38	4.5 (0)	
39	5.6 (0) 4.7 (60) 4.5 (120)	
		4.9 (60) 4.3 (120)
40	3.6 (0)	0 (60)
41	5.3 (0)	

- 41 -

iii) Microscopy analysis

A selection of the products from Examples 18-41
5 were investigated using a light microscope (Nikon UFX-II)
with a micrometer scale. The investigations were
generally performed by taking out samples of emulsified
material as formed immediately after sonication, except
for Example 31 (where the sample was withdrawn after
10 manual shaking), Example 39 (where the sample was
withdrawn after UV irradiation) and Example 40 (where
samples were withdrawn both immediately after sonication
and after redox initiation), and placing each sample
between two glass plates. The results of these
15 investigations are presented in Table 3; the time
intervals (in minutes from sonication) to microscopy
analysis are given for each sample.

Table 3
Microscopy analysis

Example No.	Time after sonication (min)	Size (diam., μm)	Comments (shape, size distribution)
25	10	4	spheres, narrow size distribution
26	10	10-25	spheres
27	10	4	spheres, narrow size distribution
28	10	4-6	spheres, narrow size distribution
29	10	variable	various shapes, broad size distribution
30	10	4-6	spheres, narrow size distribution
31	10 (after shaking)	10-100	large bubbles, unlike the sonicated samples
33	10	2-3	spheres
35	10	10-15	spheres
36	10	8-15	spheres, broad size distribution
38	10	5-10	spheres
39	10	5-10	spheres, also larger bubbles
40	30	5-10	spheres
40	30 (after redox)	variable	bubbles of irregular shape
41	10	4	spheres, narrow size distribution

- 43 -

iv) Size Exclusion Chromatography

Size Exclusion Chromatography (SEC) was performed on the freeze dried product from Example 25 using tetrahydrofuran (Rathburn HPLC quality) as eluant and refractive index as detector (Knauer, Germany). The column set used consisted of 3 x 30cm columns containing 5 μ m styrogel with pore sizes of 10⁵, 10⁴, and 500 \AA (Polymer Laboratories Ltd., England). Calibration was made against polystyrene standards (Polymer Laboratories Ltd., England). The amphiphilic monomer starting material gave a peak molecular weight of 1,600 Daltons and the polymer product gave a peak molecular weight of 22,000 Daltons, both given in polystyrene equivalents.

Using the conversion factor of 0.59 for converting from polystyrene equivalents to "real" molecular weights (the value for PEG given by Dawkins et al., J. Liq. Chromatog. 7, 1739, (1984), these correspond to molecular weights of 944 Daltons for the monomer and 13,000 Daltons for the polymer respectively.

CLAIMS

1. Contrast agents for use in diagnostic ultrasound studies comprising microbubbles of gas or a gas precursor encapsulated by non-proteinaceous crosslinked or polymerised amphiphilic moieties.
5
2. Contrast agents as claimed in claim 1 in the form of gas-filled microballoons.
10
3. Contrast agents as claimed in claim 1 or claim 2 containing biodegradable linkages selected from amide, imide, imine, ester, anhydride, acetal, carbamate, carbonate, carbonate ester and disulphide groups.
15
4. Contrast agents as claimed in claim 3 containing biodegradable crosslinking groups.
20
5. Contrast agents as claimed in claim 4 wherein the biodegradable crosslinking groups include units of formula
$$-(Y)_n.CO.O.C(R^1R^2).O.CO.(Z)_n-$$
(where Y and Z, which may be the same or different, are -O-, -S- or -NR³-; R¹ and R², which may be the same or different, are hydrogen atoms or carbon-attached monovalent organic groups or together represent a carbon-attached divalent organic group; R³ is a hydrogen atom or an organic group; and the symbols n, which may be the same or different, are zero or 1).
25
6. Contrast agents as claimed in claim 1 or claim 2 obtained from polymerisable amphiphilic moieties containing unsaturated lipophilic chains.
30
7. Contrast agents as claimed in claim 6 wherein the unsaturated lipophilic chains are oleyl or linoleyl groups or contain diacetylene groupings or acryloyl or
35

methacryloyl groupings.

8. Contrast agents as claimed in any of the preceding claims wherein the hydrophilic portion of the amphiphile contains one or more groups selected from quaternary ammonium, hydroxyl, carboxy, carboxylate ion, amide, phosphate, sulphate and sulphonate.
9. Contrast agents as claimed in claim 8 wherein the hydrophilic portion of the amphiphile is the triglyceryl moiety of a phospholipid, an iodinated X-ray contrast agent, a carbohydrate, or a choline, ethanolamine, serine or glycerol residue.
10. Contrast agents as claimed in any of claims 1 to 7 wherein the hydrophilic portion of the amphiphile is an optionally etherified polyoxyethylene glycol residue.
11. Contrast agents as claimed in claim 10 wherein the amphiphile is tetraethylene glycol mono-12-(methacryloyloxy)dodecanoate.
12. Contrast agents as claimed in claim 10 wherein the amphiphile is polyethylene glycol (550) methyl ether 12-(methacryloyloxy)dodecanoate.
13. Contrast agents as claimed in claim 10 wherein the amphiphile is polyethylene glycol (2000) methyl ether 12-(methacryloyloxy)dodecanoate.
14. Contrast agents as claimed in claim 10 wherein the amphiphile is tetraethylene glycol mono-16-(methacryloyloxy)hexadecanoate.
15. Contrast agents as claimed in claim 10 wherein the amphiphile is polyethylene glycol (350) methyl ether 16-(methacryloyloxy)hexadecanoate.

- 46 -

16. Contrast agents as claimed in claim 10 wherein the amphiphile is tetraethylene glycol mono-12-(acryloyloxy)dodecanoate.
- 5 17. Contrast agents as claimed in any of the preceding claims further containing an inorganic particulate stabiliser.
- 10 18. A process for the preparation of a contrast agent as claimed in claim 1 which consists of forming a fluid dispersion of vesicles comprising a gas or gas precursor encapsulated by amphiphilic material and thereafter crosslinking or polymerising said amphiphilic material.
- 15 19. A process as claimed in claim 11 wherein the fluid dispersion is prepared by sonication to generate an oil-in-water emulsion in which a volatile hydrocarbon is encapsulated by the amphiphilic material and said volatile hydrocarbon is partially or completely removed
20 from the vesicles after crosslinking or polymerisation of the amphiphilic material.

INTERNATIONAL SEARCH REPORT

International Appl. No. PCT/EP 92/00715

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all)⁶According to International Patent Classification (IPC) or to both National Classification and IPC
Int.C1.5 A 61 K 49/00

II. FIELDS SEARCHED

Minimum Documentation Searched⁷

Classification System	Classification Symbols
Int.C1.5	A 61 K

Documentation Searched other than Minimum Documentation
to the Extent that such Documents are Included in the Fields Searched⁸III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹

Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
P,X	WO,A,9204392 (HOLMES) 19 March 1992, see claims 1,10,11; page 4, lines 14-36; page 8, line 18 - page 9, line 3 ---	1-19
Y	EP,A,0327490 (SCHERING AG) 9 August 1989, see column 3, lines 37-45; column 4, lines 50-53; claims (cited in the application) ---	1-19
P,X	EP,A,0441468 (SCHERING AG) 14 August 1991, see column 10, line 2 - column 11, line 9; column 15, lines 1-10; claims ---	1-19
P,X	EP,A,0458745 (SINTETICA) 27 November 1991, see claims 1,8 ---	1-19 -/-

⁶ Special categories of cited documents :¹⁰

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reasons (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

⁷ "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention⁸ "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step⁹ "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.¹⁰ "A" document member of the same patent family

IV. CERTIFICATION

Date of the Actual Completion of the International Search

26-05-1992


Date of Mailing of this International Search Report

10.07.92

International Searching Authority

EUROPEAN PATENT OFFICE

Signature of Authorized Officer



III. DOCUMENTS CONSIDERED TO BE RELEVANT		(CONTINUED FROM THE SECOND SHEET)
Category	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.
Y	STN File Server, File Biosis, & Biological Abstract, vol. 79, (Philadelphia, PA, US), R.L. JULIANO et al.: "Interactions of polymerized phospholipid vesicles with cells uptake processing and toxicity in macrophages, see abstract no. 83225, & BIOCHIM. BIOPHYS. ACTA 812 (1). 1985. 42-48, see the abstract -----	1-19

INTERNATIONAL SEARCH REPORT

I-EP 92/00715

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: 1 - 9
because they relate to subject matter not required to be searched by this Authority, namely:

IN VIEW OF THE LARGE NUMBER OF COMPOUNDS WHICH ARE COMPRISED BY THE TERMS "NON-PROTEINACEOUS" OR "AMPHIPHILIC" OF CLAIM 1 THE SEARCH WAS LIMITED FOR ECONOMIC REASONS TO THE COMPOUNDS MENTIONED IN THE CLAIMS AND THE SEARCH (GUIDELINES PART 6 CHAP. 11.7, LAST SENTENCE AND CHAP. 11.3.7)

2. Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
- No protest accompanied the payment of additional search fees.

**ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO.**

EP 9200715
SA 57649

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.
The members are as contained in the European Patent Office EDP file on 01/07/92
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO-A- 9204392	19-03-92	AU-A-	8525691	30-03-92
EP-A- 0327490	09-08-89	DE-C- DE-A- AU-A- WO-A- EP-A- JP-T-	3803971 3803972 3035189 8906978 0398935 3503634	07-09-89 10-08-89 25-08-89 10-08-89 28-11-90 15-08-91
EP-A- 0441468	14-08-91	DE-A- AU-A-	4004430 7098291	14-08-91 17-10-91
EP-A- 0458745	27-11-91	AU-A- CN-A-	7614491 1056634	21-11-91 04-12-91

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.